{
  "id": "515df1d4298dcd4e5100002b",
  "type": "summary",
  "question": "What is the effect of Allopurinol on asphyxia in neonates?",
  "ideal_answer": "Allopurinol was shown in a number of clinical trial to be safe and effective for treatment of neonatal asphyxia. Allopurinol  improves short-term and long-term clinical outcomes of neonatal asphyxia. Allopurinol should be administered as soon as possible. Postulated mechanism of allopurinol action in this setting is prevention of hypoxia-perfusion injury by reduction of free radical formation.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/16428356",
    "http://www.ncbi.nlm.nih.gov/pubmed/17162192",
    "http://www.ncbi.nlm.nih.gov/pubmed/22564301",
    "http://www.ncbi.nlm.nih.gov/pubmed/22102633",
    "http://www.ncbi.nlm.nih.gov/pubmed/9445490",
    "http://www.ncbi.nlm.nih.gov/pubmed/16778717",
    "http://www.ncbi.nlm.nih.gov/pubmed/12436031",
    "http://www.ncbi.nlm.nih.gov/pubmed/20167117"
  ],
  "snippets": [
    {
      "text": "Potential neuroprotective strategies targeting different pathways leading to neuronal cell death in response to hypoxic-ischemic insult have been investigated: hypothermia, erythropoietin, iminobiotin, deferioxamine, magnesium, allopurinol, xenon, melatonin and statins.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22564301",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Allopurinol reduces the formation of free radicals, thereby potentially limiting the amount of hypoxia-reperfusion damage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102633",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "There were no differences in long-term outcome between the allopurinol-treated infants and controls. However, subgroup analysis of the moderately asphyxiated group showed significantly less severe adverse outcome in the allopurinol-treated infants compared with controls (25% vs 65%; RR 0.40, 95%CI 0.17 to 0.94).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102633",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The reported data may suggest a (neuro)protective effect of neonatal allopurinol treatment in moderately asphyxiated infants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102633",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The asphyxiated newborns treated with allopurinol had better neurologic and neurodevelopmental outcome at 12 or more months of age.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17162192",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "In newborn infants, allopurinol is being tested as a free radical scavenger to prevent brain damage caused by reperfusion and oxygenation after perinatal hypoxia and ischemia (birth asphyxia).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16778717",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Early postnatal allopurinol does not improve short term outcome after severe birth asphyxia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16428356",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The analysis showed an unaltered (high) mortality and morbidity in the infants treated with allopurinol.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16428356",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Allopurinol treatment started postnatally was too late to reduce the early reperfusion induced free radical surge.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16428356",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "One randomized trial of allopurinol showed short-term benefits but was too small to test death or disability.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12436031",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "No toxic side effects of ALLO were detected.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9445490",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "This study suggests a beneficial effect of ALLO treatment on free radical formation, CBV, and electrical brain activity, without toxic side effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9445490",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001238",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001237",
    "http://www.biosemantics.org/jochem#4273300",
    "http://www.disease-ontology.org/api/metadata/DOID:11088",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007231",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000493"
  ]
}